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Despite a huge number of studies that have established the beneﬁcial effects of statins
in cardiovascular diseases, the mechanism of action of these drugs remains puzzling
and indeed one of the most challenging research topics for clinicians and biologists in
cardiology.
Statins are highly effective in lowering concentrations of serum cholesterol through
3-hydroxymethylglutaryl coenzyme A reductase inhibition. But statins also exert numer-
ous lipid-independent effects. These ‘pleiotropic’ actions include improved endothelial
function, stabilization of vulnerable plaques, and anti-inﬂammatory and antithrombotic
effects [1]. Myocardial effects have also been reported including modulation of sig-
nalling pathways involved in hypertrophic remodelling of the heart [2], together with
cardioprotective effects, notably against oxidative stress [3]. These drugs also show antiar-
rhythmic effects that may result from a reduction of the arrhythmogenic substrate,
notably ﬁbrosis in the context of atrial ﬁbrillation [4,5]. Cholesterol is an important
determinant in the function of ionic channels and in the electrical properties of mem-reductase;
Rosuvastatine;
Syndrome coronarien
aigu
branes. Recent studies report that alterations in membrane-cholesterol content are
associated with marked changes in potassium channel activity both in endothelial vas-
cular cells [6] and cardiac myocytes [7]. These effects of statins on ion channels could
lead to vasodilatation or modulation of myocardial repolarization and antiarrhythmic
properties.
 Editorial for the Centaurus trial, Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients
with an acute coronary syndrome: The CENTAURUS trial design, Lablanche J.-M, Danchin N., Farnier M., Tedgui A., Vicaut E.,
Alonso J., Crean P., Leone A., Morais J., Santini M., Licour M., Farah M., Tardif J.-C., 2008;101(6):399—406.
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During an acute coronary syndrome (ACS) plasma-
holesterol levels decrease, and may be explained by a
arallel increase in low-density-lipoprotein (LDL) recep-
or activity and increased cholesterol catabolism. These
ould result in an enhanced delivery of cholesterol to
ells involved in tissue-repair mechanisms, or may reﬂect
on-speciﬁc acute phase responses, for instance secondary
o the inﬂammatory phenomenon [8—10].
Rosuvastatin is a recent statin with a potent cholesterol-
owering effect and [good?] safety proﬁle, as shown in
ifferent trials upon switching from alternative statins that
ere not fully effective. Rosuvastatin is a synthetic hydrox-
methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor
ith distinctive pharmacological (relatively hydrophilic)
nd pharmacokinetic properties. In comparison with other
tatins, rosuvastatin exhibits a greater number of binding
nteractions with HMG-CoA reductase, a high afﬁnity for
he enzyme’s active site, and potent inhibition of choles-
erol synthesis in hepatocytes [11]. In a broad spectrum
f adult patients with dyslipidaemias, several clinical
tudies have shown that rosuvastatin (5—80mg) effectively
educed concentrations of total cholesterol, triglycerides,
DL-cholesterol (LDL-C), non—high-density lipoprotein
holesterol (non—HDL-C), and increased apolipoprotein
apo) A-I and HDL-C [12,13]. Compared with other statins,
osuvastatin is the most potent, signiﬁcantly increasing apo
-I by nearly 9% [13]. In addition to effectively reducing
lasma cholesterol and LDL levels, a considerable clinical
nterest has been developed with rosuvastatin for its ability
o increase concentrations of HDL-C and apo A-I. It is well
stablished that HDL bears an inverse relationship to the
evelopment of atherosclerotic coronary heart disease
14]. Apo A-1 is a major protein of HDL, and the cardio-
rotective effects of HDL have been attributed largely to
he ability of apo A-I—containing HDL particles to initiate
holesterol efﬂux and thereby facilitate the removal of
xcess cholesterol from peripheral tissues and its delivery
o the liver for elimination through the reverse cholesterol
ransport pathway. The other potent statin, atorvastatin,
as little or no ability to increase concentrations of HDL-C,
nd this may be a disadvantage in patients with metabolic
yndrome or diabetes, in whom low HDL-cholesterol is a key
eature.
Recently, the ECLIPSE (Evaluation to Compare Lipid
owering effects of rosuvastatin and atorvastatin In force
itrated subjects: a Prospective Study of Efﬁcacy and tolera-
ility) study showed that rosuvastatin (10—40mg) achieved
ore frequently the NCEP ATP III LDL-C goal of <100mg/dL
2.5mmol/L) compared to atorvastatin (10—80mg), with
he same tolerability in high-risk patients with hypercholes-
erolaemia [15]. This is in line with data from the DISCOVERY
Direct Statin Comparison of LDL-C Values: An Evaluation
f Rosuvastatin Therapy Compared with Atorvastatin) trial
16], which showed that rosuvastatin 10mg was more potent
n decreasing LDL-C and total cholesterol and in increasing
DL-C than atorvastatin 10mg in a 12-week randomized
rial including more than 900 subjects with hypercholes-
erolaemia who were at high risk for coronary heart
isease.
Apart from its potent efﬁcacy on lipid parameters, rosu-
astatin exerts a variety of so-called ‘pleiotropic’ actions
hat may result in clinical beneﬁt. A substantial number of
b
o
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xperimental and clinical studies have indicated favourable
ffects of rosuvastatin on endothelial function, oxidized
DL, inﬂammation, plaque stability, vascular remodelling,
aemostasis, and the myocardium [17]. Whether the
stablished ‘pleiotropy’ and/or lipid-lowering efﬁcacy of
osuvastatin may translate into reduced morbidity and mor-
ality remains to be demonstrated in ongoing clinical trials.
t present, no large-scale primary or secondary prevention
linical trials document either its long-term safety or effec-
iveness in preventing cardiovascular events.
The design of the CENTAURUS study [18] presented
n this issue of Archives of Cardiovascular Diseases will
rovide further data on the relative efﬁcacy of rosuvas-
atin and atorvastatin on the apolipoprotein B:A ratio
apoB/apoA-1) in patients with an ACS. Yusuf et al. [19]
learly demonstrated in the worldwide INTERHEART study
hat the apoB/apoA-1 ratio was the strongest predictor
f myocardial infarction, and that this ratio was a better
redictor than other relevant factors such as smoking,
ypertension or diabetes. While the predictive value of this
atio has been poorly evaluated in patients post-ACS it is
predictor of vascular events in primary prevention [20].
n the LIPID (Long-term Intervention with Pravastatin in
schaemic Disease) trial [21], apoB and the combination of
otal and HDL-C were the most important lipid parameters
ssociated with event reduction in secondary prevention.
he CORALL (COmpare the effect of Rosuvastatin with
torvastatin on apoB/apoA-1 ratio in patients with Type 2
iabetes meLLitus and dyslipidaemia) study [22] showed
hat rosuvastatin (10—40mg) led to a greater reduction
f apoB/apoA-1 compared with atorvastatin (10—80mg;
40.5% vs —35.8%, p < 0.05 at week 18) in patients with type
diabetes and dyslipidaemia but without an ACS. Recently,
osuvastatin combined with candesartan reduced plaque
rea in a diabetes-accelerated atherosclerosis mice model
23].
As stated [18], the concentration of high-sensitivity
-reactive protein (hs-CRP) after an ACS seems to be an
ndependent predictor of cardiovascular events beyond
he LDL-C level. The comparative effect of rosuvastatin
nd atorvastatin on this inﬂammatory marker (secondary
utcome) will be evaluated in this trial, including more
han 1000 patients with an ACS who were followed for 3
onths. However, the CENTAURUS study was not designed
o solve the question as to whether the decrease of hs-CRP
rotects from cardiovascular events after an ACS indepen-
ently of any LDL-C reduction because of a lack of power
nd a too short follow-up. The JUPITER (Justiﬁcation for
he Use of statins in Primary prevention: an Intervention
rial Evaluating Rosuvastatin) study [24] is a randomized,
ouble-blind, placebo-controlled primary prevention trial
f rosuvastatin (20mg) among persons with average to low
evels of LDL-C who were at increased cardiovascular risk
ue to elevated plasma concentrations of the inﬂammatory
iomarker hs-CRP. The results from this study will provide
mportant and clinically relevant information on primary
revention among patients (>17 000) who do not currently
ualify for lipid-lowering therapy. However, this study has
een interrupted prematurely (evidence of beneﬁt?).
Finally, the importance and need for early initiation
f statin therapy after an ACS has been demonstrated in
meta-analysis [25]. These data support intensive LDL-C
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reduction post-ACS. If the CENTAURUS trial is able to pro-
vide information on the ability of rosuvastatin to decrease
the apoB/apoA-1 ratio in ACS patients over atorvastatin,
this will lengthen the window of opportunity to address this
ratio before hospital discharge but its prognostic value will
still be unavailable.
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